265 related articles for article (PubMed ID: 28161904)
1. Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer.
Satoh M; Takano S; Sogawa K; Noda K; Yoshitomi H; Ishibashi M; Mogushi K; Takizawa H; Otsuka M; Shimizu H; Miyazaki M; Nomura F
Cancer Sci; 2017 Apr; 108(4):795-803. PubMed ID: 28161904
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of Cofilin Isoforms in Patients With Pancreatic Ductal Adenocarcinoma.
Islam S; Kitagawa T; Kuramitsu Y
Pathol Oncol Res; 2021; 27():1609821. PubMed ID: 34257623
[No Abstract] [Full Text] [Related]
3. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients.
Tian M; Cui YZ; Song GH; Zong MJ; Zhou XY; Chen Y; Han JX
BMC Cancer; 2008 Aug; 8():241. PubMed ID: 18706098
[TBL] [Abstract][Full Text] [Related]
5. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.
Chen J; Chen LJ; Xia YL; Zhou HC; Yang RB; Wu W; Lu Y; Hu LW; Zhao Y
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1117-27. PubMed ID: 23546595
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma.
Chen J; Chen LJ; Yang RB; Xia YL; Zhou HC; Wu W; Lu Y; Hu LW; Zhao Y
Med Oncol; 2013; 30(2):583. PubMed ID: 23609192
[TBL] [Abstract][Full Text] [Related]
7. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
[TBL] [Abstract][Full Text] [Related]
8. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Chen X; Li C; Zong G; Zhou G; Wan C
Exp Mol Pathol; 2016 Oct; 101(2):176-186. PubMed ID: 27498047
[TBL] [Abstract][Full Text] [Related]
9. Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer.
Shimazaki R; Takano S; Satoh M; Takada M; Miyahara Y; Sasaki K; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Sogawa K; Motohashi S; Nomura F; Miyazaki M; Ohtsuka M
Cell Oncol (Dordr); 2021 Aug; 44(4):937-950. PubMed ID: 34075561
[TBL] [Abstract][Full Text] [Related]
10. Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus.
Kolb A; Rieder S; Born D; Giese NA; Giese T; Rudofsky G; Werner J; Büchler MW; Friess H; Esposito I; Kleeff J
Cancer Biol Ther; 2009 Aug; 8(16):1527-33. PubMed ID: 19571666
[TBL] [Abstract][Full Text] [Related]
11. CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis.
Shi J; Guan X; Zhan F; Liu C; Li Z; Yao Y; Wang B; Lou C; Zhang Y
Cancer Biol Ther; 2019; 20(9):1290-1299. PubMed ID: 31311398
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
[TBL] [Abstract][Full Text] [Related]
13. NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma.
Wan C; Gong C; Ji L; Liu X; Wang Y; Wang L; Shao M; Yang L; Fan S; Xiao Y; Wang X; Li M; Zhou G; Zhang Y
Mol Cell Biochem; 2015 Dec; 410(1-2):25-35. PubMed ID: 26276310
[TBL] [Abstract][Full Text] [Related]
14. Serum and tissue metallome of pancreatic ductal adenocarcinoma.
Byeon S; du Toit-Thompson T; Hipperson L; Maloney S; Wenzel R; Gill AJ; Samra JS; Mittal A; Sahni S
Cancer Sci; 2024 May; 115(5):1446-1458. PubMed ID: 38438247
[TBL] [Abstract][Full Text] [Related]
15. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma.
Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L
Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma.
Li HB; Wang JL; Jin XD; Zhao L; Ye HL; Kuang YB; Ma Y; Jiang XY; Yu ZY
BMC Cancer; 2021 Sep; 21(1):1039. PubMed ID: 34530774
[TBL] [Abstract][Full Text] [Related]
18. Survivin expression and serum levels in pancreatic cancer.
Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
[TBL] [Abstract][Full Text] [Related]
19. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Koga A; Sato N; Kohi S; Yabuki K; Cheng XB; Hisaoka M; Hirata K
Pancreatology; 2017; 17(1):115-122. PubMed ID: 28012880
[TBL] [Abstract][Full Text] [Related]
20. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
